SPCC297.05 Antibody

What are the key specifications of the SPCC297.05 antibody for research applications?

The SPCC297.05 antibody is available as a polyclonal antibody raised in rabbit using recombinant Schizosaccharomyces pombe (strain 972/ATCC 24843) SPCC297.05 protein as the immunogen. This antibody has been affinity-purified and is supplied in liquid form containing 50% glycerol and 0.01M PBS (pH 7.4) with 0.03% Proclin 300 as a preservative. The antibody is specifically reactive to SPCC297.05 in S. pombe and has been validated for ELISA and Western Blot applications to ensure proper identification of the antigen. For optimal preservation, storage at -20°C or -80°C is recommended, with repeated freeze-thaw cycles being avoided to maintain antibody integrity and performance .

How does antibody validation for SPCC297.05 compare to standard validation practices in the field?

Antibody validation for SPCC297.05 follows industry-standard practices similar to those used for other research antibodies. The antibody has undergone validation specifically for ELISA and Western Blot applications, which aligns with common validation approaches described in antibody databases like PLAbDab. According to current standards in the field, comprehensive antibody validation should include:

• Specificity testing through multiple applications (SPCC297.05 is validated for ELISA and WB)

• Determination of optimal working concentrations

• Verification of target recognition in relevant biological samples

• Assessment of cross-reactivity with related proteins

These validation steps are essential for ensuring reproducible research outcomes, especially given that antibodies represent a significant source of variability in experimental results. The SPCC297.05 antibody validation falls within the established framework used for other research antibodies in the field .

What are the considerations for optimizing SPCC297.05 antibody dilutions in Western blot experiments?

Optimizing antibody dilutions for SPCC297.05 in Western blot experiments requires careful consideration of several factors:

A titration experiment is strongly recommended when first using the antibody, where serial dilutions are tested against a known positive sample. This approach allows researchers to identify the optimal dilution that provides the strongest specific signal with minimal background. For SPCC297.05 specifically, the antibody's polyclonal nature means it recognizes multiple epitopes on the target protein, which can enhance signal sensitivity but may require additional optimization to minimize cross-reactivity .

How can researchers integrate SPCC297.05 antibody-based approaches with other experimental techniques in yeast research?

Researchers can create powerful multi-dimensional datasets by integrating SPCC297.05 antibody-based approaches with complementary techniques:

• Genomic integration: Combining antibody detection of native SPCC297.05 with strains containing genomically tagged versions (e.g., GFP-tagged SPCC297.05) enables verification of antibody specificity while providing complementary protein localization data.

• Interactome analysis: Using SPCC297.05 antibody for co-immunoprecipitation followed by mass spectrometry can identify protein interaction partners, which can be further validated through techniques like yeast two-hybrid assays.

• Transcriptomic correlation: Pairing protein expression data from Western blots using SPCC297.05 antibody with RNA-seq data allows researchers to examine the relationship between mRNA and protein levels, providing insights into post-transcriptional regulation.

• Functional genomics integration: Correlating phenotypic data from SPCC297.05 deletion or mutation strains with antibody-derived protein expression data can reveal structure-function relationships.

What are the methodological considerations for using SPCC297.05 antibody in chromatin immunoprecipitation (ChIP) experiments?

While the SPCC297.05 antibody is not explicitly validated for ChIP applications in the available data, researchers interested in exploring this application should consider the following methodological approach:

• Preliminary assessment: Test antibody specificity through Western blot analysis of nuclear extracts to confirm target recognition in the chromatin environment.

• Cross-linking optimization: Determine optimal formaldehyde cross-linking conditions (typically 1-1.5%, 10-15 minutes) specific for S. pombe cells, as fixation affects epitope accessibility.

• Sonication parameters: Optimize sonication conditions to generate 200-500 bp DNA fragments while preserving protein epitopes.

• Antibody concentration: A higher antibody concentration than used for Western blot is typically required (approximately 2-5 μg antibody per ChIP reaction).

• Validation controls: Include:

  • Input sample (pre-immunoprecipitation chromatin)

  • Non-specific IgG control

  • Positive control target (known chromatin-associated protein)

  • SPCC297.05 knockout strain (if available)

• Sequential ChIP consideration: If investigating co-localization with other proteins, sequential ChIP may be necessary.

Since the antibody is polyclonal, batch-to-batch variation should be carefully monitored through consistent control experiments .

What are the recommended sample preparation methods for detecting SPCC297.05 in different S. pombe growth phases?

The detection of SPCC297.05 across different growth phases requires careful consideration of sample preparation methods:

All extraction methods should incorporate:

• Protease inhibitor cocktail (PMSF, leupeptin, pepstatin A)

• Phosphatase inhibitors if phosphorylation is suspected

• Immediate denaturation in sample buffer for Western blot applications

• Maintenance of native conditions for immunoprecipitation

These approaches help ensure that SPCC297.05 is effectively extracted in its native state across different growth conditions, enabling meaningful comparisons of expression and modification patterns throughout the cell cycle and in response to environmental changes .

How can researchers validate the specificity of SPCC297.05 antibody for immunofluorescence applications?

Validating SPCC297.05 antibody for immunofluorescence requires a systematic approach:

• Genetic controls: Compare staining between wild-type and SPCC297.05 deletion/knockdown strains. The absence of signal in deletion strains provides strong evidence for specificity.

• Epitope competition assay: Pre-incubate the antibody with excess purified antigen (recombinant SPCC297.05) before staining. The disappearance of signal confirms epitope-specific binding.

• Recombinant tag correlation: Compare localization patterns between antibody staining of native SPCC297.05 and fluorescently tagged SPCC297.05 (e.g., GFP-SPCC297.05) expressed at physiological levels.

• Batch consistency testing: When using new antibody lots, perform side-by-side comparisons with previously validated lots to ensure consistent localization patterns.

• Technical controls:

  • Secondary-only control to assess background fluorescence

  • Pre-immune serum control (if available) to evaluate non-specific binding

  • Co-staining with known markers of relevant subcellular compartments

• Signal quantification: Develop objective quantification methods for signal intensity and localization patterns to enable statistical validation across experimental replicates.

These validation steps ensure that immunofluorescence results accurately reflect SPCC297.05 localization rather than artifacts or non-specific staining .

What are the critical parameters for optimizing ELISA protocols using SPCC297.05 antibody?

Optimizing ELISA protocols with SPCC297.05 antibody involves careful adjustment of several critical parameters:

Based on similar antibody applications, the following starting protocol is recommended:

• Coat plates with 50-100 ng/well of purified target protein

• Block with 3% BSA in PBS-T

• Use SPCC297.05 antibody at 0.5-1 μg/mL (titrate in initial experiments)

• Incubate overnight at 4°C

• Detect with appropriate enzyme-conjugated secondary antibody

This approach provides a foundation for further optimization based on specific experimental requirements and sample types .

What are common issues encountered when using SPCC297.05 antibody in Western blots and how can they be resolved?

For SPCC297.05 antibody specifically, researchers should note that as a polyclonal antibody, it recognizes multiple epitopes on the target protein. This can be advantageous for detection sensitivity but may contribute to batch-to-batch variation. Including consistent positive controls is particularly important for experiments spanning multiple antibody lots .

How can researchers assess and ensure lot-to-lot consistency when working with SPCC297.05 antibody?

Ensuring lot-to-lot consistency with SPCC297.05 antibody requires systematic quality control procedures:

• Reference sample testing: Maintain frozen aliquots of a standard positive control sample (e.g., wild-type S. pombe extract). Test each new antibody lot against this reference to compare:

  • Signal intensity at standardized exposure times

  • Background levels

  • Banding pattern specificity

• Titration comparison: Perform parallel titration experiments (e.g., 1:500, 1:1000, 1:2000, 1:5000 dilutions) with old and new lots to compare dose-response curves rather than single-point measurements.

• Quantitative metrics: Develop objective measurement criteria:

  • Signal-to-noise ratio calculation

  • Specific band intensity relative to total protein load

  • Limit of detection determination

• Application-specific validation: For each critical application (Western blot, ELISA, etc.), perform application-specific validation with each new lot.

• Documentation system: Establish a laboratory database recording:

  • Lot number and date received

  • Validation experiment results

  • Optimal working dilutions by application

  • Any observed differences from previous lots

• Supplier quality documentation: Request and maintain certificate of analysis documents from the supplier for each lot, noting any changes in production methods.

This systematic approach enables researchers to maintain experimental consistency despite the inherent variability in polyclonal antibody production .

What approaches can improve signal detection when working with low-abundance SPCC297.05 protein samples?

When working with low-abundance SPCC297.05 protein samples, several approaches can significantly improve detection sensitivity:

• Sample enrichment techniques:

  • Immunoprecipitation to concentrate target protein before Western blotting

  • Subcellular fractionation to reduce sample complexity

  • TCA precipitation to concentrate proteins from dilute samples

• Signal amplification methods:

  • Enhanced chemiluminescence (ECL) plus or advanced ECL substrates

  • Tyramide signal amplification (TSA) for immunofluorescence

  • Biotin-streptavidin amplification systems

• Detection system optimization:

  • Extended exposure times with low-noise detection systems

  • Cooled CCD camera imaging instead of film

  • Cumulative signal collection for digital imaging systems

• Protocol modifications:

  • Extended primary antibody incubation (overnight at 4°C)

  • Reduced washing stringency (shorter washes, lower detergent concentration)

  • Use of signal enhancer solutions during antibody incubation

• Alternative detection formats:

  • Capillary Western systems (e.g., Wes, Jess) with improved sensitivity

  • Microwestern arrays for multiplexed detection

  • ELISA-based detection instead of traditional Western blotting

A combination of these approaches can improve SPCC297.05 detection by 10-100 fold compared to standard protocols, enabling research on proteins expressed at low physiological levels or in limiting sample conditions .

How can SPCC297.05 antibody be incorporated into broader proteomics workflows in yeast research?

SPCC297.05 antibody can be strategically incorporated into comprehensive proteomics workflows:

• Antibody-based enrichment prior to mass spectrometry:

  • Immunoprecipitation of SPCC297.05 and associated proteins for interaction studies

  • Enrichment of post-translationally modified forms for PTM mapping

  • Isolation of protein complexes for compositional analysis

• Validation of mass spectrometry findings:

  • Western blot confirmation of differentially expressed proteins identified by MS

  • Verification of protein interactions detected in large-scale interactome studies

  • Confirmation of protein localization predicted by proteome-wide screens

• Integration with functional genomics data:

  • Correlation of protein expression levels (antibody-based) with transcriptomics data

  • Phenotypic analysis of SPCC297.05 mutants coupled with expression profiling

  • Temporal studies integrating protein dynamics with metabolomic changes

• Development of targeted assays:

  • Creation of quantitative Western blot protocols calibrated against SRM/MRM MS data

  • Multiplexed antibody arrays incorporating SPCC297.05 detection

  • Proximity ligation assays to validate predicted protein-protein interactions

This integrated approach positions SPCC297.05 antibody as a valuable tool within the broader context of systems biology research in S. pombe, enabling validation and extension of high-throughput proteomics findings .

What are the considerations for cross-species application of SPCC297.05 antibody research?

Cross-species application of SPCC297.05 antibody research requires careful consideration of evolutionary relationships and epitope conservation:

• Homology assessment:

  • Conduct bioinformatic analysis to identify potential homologs in related species

  • Align sequences to determine regions of highest conservation

  • Evaluate conservation specifically within the immunogenic regions used to generate the antibody

• Cross-reactivity testing protocol:

  • Systematic testing against extracts from related yeast species (S. japonicus, S. octosporus)

  • Western blot analysis with gradient loading to determine detection thresholds

  • Comparative immunoprecipitation efficiency across species

• Validation requirements:

  • Additional controls for cross-species applications

  • Side-by-side comparison with species-specific antibodies where available

  • Genetic verification using deletion/knockdown strains in each species

• Application optimization:

  • Species-specific protocol modifications (lysis conditions, buffer compositions)

  • Adjusted antibody concentrations for different species

  • Modified detection systems based on expression levels in different organisms

• Interpretation considerations:

  • Accounting for potential differences in protein function across species

  • Recognition of species-specific post-translational modifications

  • Awareness of potential differences in protein-protein interactions

Through careful validation and optimization, SPCC297.05 antibody research may provide valuable comparative insights across evolutionarily related species, potentially revealing conserved and divergent aspects of protein function .

How can computational approaches enhance antibody-based studies of SPCC297.05?

Computational approaches can significantly enhance antibody-based studies of SPCC297.05:

• Epitope prediction and antibody design:

  • In silico analysis of SPCC297.05 protein structure to identify optimal epitope regions

  • Computational prediction of antibody-antigen binding characteristics

  • Structure-based design of optimized immunogens for improved antibody generation

• Data integration platforms:

  • Integration of antibody-derived data with existing -omics databases like PLAbDab

  • Correlation of SPCC297.05 expression patterns with genome-wide datasets

  • Network analysis incorporating antibody-validated protein interactions

• Image analysis for localization studies:

  • Automated quantification of immunofluorescence signal intensity and distribution

  • Machine learning algorithms for pattern recognition in subcellular localization

  • 3D reconstruction from confocal z-stacks to visualize spatial relationships

• Quantitative Western blot analysis:

  • Automated band detection and quantification algorithms

  • Statistical tools for comparing expression across multiple conditions

  • Normalization approaches for cross-experiment comparability

• Quality control methodologies:

  • Statistical frameworks for assessing antibody validation results

  • Variance component analysis to identify sources of experimental variability

  • Bayesian approaches for integrating multiple lines of antibody validation evidence